



ecnm-conference.com

ECNM 2026 – Annual Meeting

Thursday 17th

Day 1 | September 2026

12:00

Registration &
Welcome Coffee

12:20-12:40

Welcome & Introduction
Juliana Schwaab
Andreas Reiter
Wolf-Karsten Hofmann

12:40-13:00

Status of the ECNM
in 2026 und future
perspectives
Peter Valent &
Frank Siebenhaar

13:00-14:00

Researcher of the Year
Introduction by Frank
Siebenhaar & Peter Valent
Lecture: Clinical
implications of co-
existing IgE-dependent
allergies in patients with
mastocytosis by Patrizia
Bonadonna

14:00-15:10

Session 1: The
pathologists view on SM
and AHN
Chairs: Michael Doubek,
Karl Sotlar
Diagnosis and subtyping
of AHN by Karl Sotlar
Bringing together WHO
and ICC by Tracy I. George
My most challenging
cases by Hans-Peter
Horny
Discussion

15:10-15:45

Coffee Break

Thursday 17th

Day 1 | September 2026

15:45-17:15

Session 2: Diagnostic
challenges
Chairs: Friederike
Wortmann, Saskia Klein
Serum tryptase: pitfalls
and perspectives by
Lawrence B. Schwartz
MCAD and HaT:
definitions, diagnostic
criteria and prognostic
variables by Peter Valent
HaT in the Clinic:
Risk, symptoms, and
therapeutic implications
by Jonathan J. Lyons
KIT D816V, cytogenetics
and additional somatic
mutations by Nicholas C.P.
Cross
Discussion

17:15-18:25

Session 3: Genetic
complexity of SM and AHN
Chairs: Julien Rossignol,
Tracy I. George
Genetic pattens and
lineage involvement in SM
and AHN by Alberto Orfao
How additional mutations
shape diagnosis and
prognosis in mastocytosis
by Johannes Lübke
Novel markers, targets and
technologies in SM & AHN
by Gregor Hörmann
Discussion

18:25-18:40

Summary of day 1
announcements by Peter
Valent

19:15-22:00

Reception at
Rheinterassen
Sponsored by Cogent

Friday 18th

Day 2 | September 2026

08:00

Registration & Welcome

08:30-10:00

Session 4: ECNM
registry projects part 1
Chairs: Peter Valent,
Wolfgang R. Sperr
Overview of the Registry
and the Status of Project
Waves by Wolfgang R.
Sperr
Overview of Registry
Projects W1-W9 by Peter
Valent
PR1: analysis of various
age groups by Marc
Emmenegger
PR7: Spectrum of
mediator-related
symptoms by Massimo
Triggiani
PR8: Treatment of patients
with mastocytosis by
Chiara Elena &
Wolfgang R. Sperr
PR12: Course and
prognosis in SSM by
Matthias Christen
PR15: Clinical features
and course in various
forms of ASM by Khalid
Shoumariyeh
PR28: Clinical impact of
reported co-morbidities
by Olivier Hermine, Julien
Rossignol & Michel Arock
Discussion

10:00-10:30

Coffee Break





ecnm-conference.com

ECNM 2026 – Annual Meeting

Friday 18th

Day 2 | September 2026

10:30-11:50

Session 4: ECNM registry projects part 2

Chairs: Peter Valent,
Wolfgang R. Sperr

PR30: Impact of monocytes in mastocytosis by Friederike Wortmann

PR31: prognostic impact of inflammation parameters by Michael Makris & Fotios Koliofotis

PR32: Impact of region and referral site by Rebekka Linhart

PR37: Impact of additional mutations in SM on OS and PFS by Michael Doubek

PR38: Impact of specific allergies in mastocytosis by Hanneke Oude Elberink

PR40: WHO versus ICC classifications in mastocytosis by Massimiliano Bonifacio

PR46: Validation of the IPSM with an updated data set by Wolfgang R. Sperr

New projects, proposals and project waves 2026/2027 by Peter Valent

11:50-12:00

Group Photo

12:00-13:00

Lunch break
(+ closed session of the ECNM registry steering committee)

Friday 18th

Day 2 | September 2026

13:00-14:30

Session 5: Anaphylaxis and MCAS

Chairs: Clive Grattan,
Deborah Christen

Allergies and intolerance in mastocytosis: myth, mechanisms and triggers by Hanneke Oude Elberink

Hymenoptera venom allergy: risk stratification and management by Marek Niedoszytko

Concepts, controversies and criteria around MCAD by Theo Gulen

MCAD: clinical reality and unmet needs by Mariana Castells

Discussion

14:30-16:30

Session 6: Organ involvement and pediatric disease

Chairs: Melody C. Carter,
Vito Sabato

Cutaneous involvement in SM: clinical manifestations and suitability as response marker to treatment by Karin Hartmann

Differential diagnosis to cutaneous lesions in CM and SM: diagnostic measures, assays and algorithms by Clive Grattan

Diagnosis & management of pediatric mastocytosis: the challenge for dermatologist and paediatrician by Magdalena Lange

Advanced mastocytosis in children: diagnosis and therapy by Melody C. Carter

Osteopathy in SM: diagnosis & new treatment options by Massimo Triggiani

Discussion

Friday 18th

Day 2 | September 2026

16:20-17:00

Coffee Break

17:00-18:10

Session 7: Multidisciplinary board on ISM - Phenotype, basic treatment and TKIs

Presentation + discussion in the board with special attention on:

Complexity of clinical phenotype: symptom burden, GI involvement, bone disease by Sigurd Broesby-Olsen

Bare minimum or going the extra mile for diagnosis of SM by Vito Sabato

Strengths and limitations of basic treatment by Friederike Wortmann

Pros and cons TKI treatment by Deepti Radia
Summary by Deepti Radia

18:10-18:50

Keynote lecture 1

Introduction by Peter Valent

Diagnosis and therapy of MCAS: status 2026 by Cem Akin

18:50-19:00

Summary of day 2 and announcements by Peter Valent

19:30

Dinner at Luisenpark,
Weißer Pavillon,
Gartenschauweg 18,
68165 Mannheim

Sponsored by Blueprint



ecnm-conference.com

ECNM 2026 – Annual Meeting

Saturday 19th

Day 3 | September 2026

08:00

Registration & Welcome

08:30-10:00

Session 8:
Multidisciplinary Board on AdvSM – TKIs and beyond
Presentation + discussion in the board with special attention on:

Treatment indication (which/when/why) by Andreas Reiter

Overview on efficacy of TKI therapy in SM by Jens Panse

Approach to ASM, MCL, MCL-AHN and SM-AML by Olivier Hermine

The dark side of TKI therapy: toxicity, resistance and progression by Juliana Schwaab

The place for allogeneic HCT in the therapeutic algorithm of SM in the TKI era: who and when to transplant? by Deborah Christen

Summary by Jens Panse

10:00-10:45

Keynote lecture 2

Introduction by Andreas Reiter

SM in 2026 and future directions by Jason Gotlib

10:45-11:15

Coffee Break

Saturday 19th

Day 3 | September 2026

10:45-12:15

Session 9: Special Issues and disease variants

Chairs: Jason Gotlib, Alberto Orfao

Mast cell leukemia and MCL-like cell lines by Michel Arock

Symptom assessment in mastocytosis by Frank Siebenhaar

Smoldering systemic mastocytosis by Wolfgang R. Sperr

KIT D816V negative SM by Iván Alvarez-Twose
Discussion

12:15-13:15

Lunch Break

13:15-15:00

Session 10: Short communications: hot topics/oral abstracts

Chairs: Andreas Hochhaus, Andreas Reiter

Evaluation of Bone Formation Marker Changes in Summit - an exploratory analysis by Boggs

Long term skeletal Outcomes of zoledronate therapy for SM related bone disease reveal different trajectories in patients w/o Anaphylaxis by Aldegheri

Efficacy and Safety of Bezuclastinib in Patients with advanced systemic mastocytosis (Apex) by Radia

Saturday 19th

Day 3 | September 2026

Outcomes, leukemic transformation and impact of KIT TKIs in SM-AHN by Rossignol

Modeling Systemic Mastocytosis with AHN: Effects of KITD814V and JAK2V617F in a hematopoietic mouse model by Sheremeti

A roadmap towards Targeting KIT D816V in Mastocytosis with Non-TKI Compounds by Zenke

Mice expressing KITD814V in the Mast cell lineage Show SM Phenotypic skin lesions that can be reversed by TKI treatment by Stivala

Avapritinib improves QOL in ISM - a prospective nationwide real world study by Gourguechon

Clinical manifestations associated with HAT gene dosage, anaphylaxis and SM by Fratessa

Repeated basal serum tryptase elevation is associated with anaphylaxis in pediatric mast cell disorders by Mol

15:00-15:15

Summary of day 3 and final announcements by Peter Valent, Frank Siebenhaar, Juliana Schwaab, Andreas Reiter

15:15-15:45

Coffee Break



ecnm-conference.com

ECNM 2026 – Annual Meeting

Saturday 19th

Day 3 | September 2026

15:45-17:00

PATIENT FORUM

Chairs: Karin Hartmann,
Frank Siebenhaar, Juliana
Schwaab, Andreas Reiter,
Peter Valent

Impact of SM on QOL and
daily life activities Patients
Q/A and discussion by
Karin Hartmann

Patients' views and
recommendations to the
scientific community by N.
Hegmann/J. Kurz

MASTHAVE APP tools to
improve patient-doctor
communication by Frank
Siebenhaar

Special challenges
for patients with
mastocytosis by J. Hobarts
Q&A

